Effects of Qishenyiqi Dripping Pill on Pulmonary Function in Chronic Obstructive Pulmonary Disease
American Journal of Internal Medicine
Volume 4, Issue 1, January 2016, Pages: 1-4
Received: Dec. 28, 2015; Accepted: Jan. 18, 2016; Published: Jan. 31, 2016
Views 3710      Downloads 76
Authors
Lingyun Gao, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, P. R. China
Hui Ren, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, P. R. China
Article Tools
Follow on us
Abstract
Objective: To investigate the effects of Qishenyiqi Dripping Pill (QDP) on pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Methods: 97 patients with chronic obstructive pulmonary disease admitted to the general wards of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital randomized plus into experimental group (53 cases) and control group (44 cases) from October 2014 to November 2015. Twice daily QDP 1000mg for experimental group based on the treatment of control group in this study, pulmonary function of two groups was compared. Results: After treatment, FEV1 from 1.36±0.12L to1.60±0.22L in experimental group, and from 1.42±0.25 to 1.51±0.16L in control group. More statistically significant was found in experimental group, P value<0.05. FEV1/FVC from 56.3±6.39% to 64.32±5.21% in experimental group, and from 56.8±8.84% to 57.33±6.56% in control group. More statistically significant was found in experimental group, P value<0.05. MMEF from 56.80±18.22% to 67.45±7.55% in experimental group, and from 55.39±20.12% to 60.22±6.01% in control group. More statistically significant was found in experimental group, P value<0.05. Conclusions: Qishenyiqi Dripping Pill can significantly improved pulmonary function of patient with chronic obstructive pulmonary disease.
Keywords
Qishenyiqi Dripping Pills, Chronic Obstructive Pulmonary Disease, Pulmonary Function
To cite this article
Lingyun Gao, Hui Ren, Effects of Qishenyiqi Dripping Pill on Pulmonary Function in Chronic Obstructive Pulmonary Disease, American Journal of Internal Medicine. Vol. 4, No. 1, 2016, pp. 1-4. doi: 10.11648/j.ajim.20160401.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). (Updated 2015) [EB/OL]. http://www.goldcopd.org/ Global Initiative for Chronic Obstructive Lung Disease.
[2]
Bose P, Bathri R, Kumar L, et al. Role of oxidative stress & transient receptor potential in chronic obstructive pulmonary disease. Indian J Med Res. 2015; 142(3): 245-60.
[3]
Lingyun Gao, Hui Ren, et al. IGC in the treatment of hyperglycemia in patients with an acute exacerbation of COPD: a prospective study. Journal of Aging Research and Clinical Practice. 2014, 3(3) 159-162.
[4]
Dongjie Ding, quanying He. Advances in diagnosis and treatment of COPD. Chinese journal of tuberculosis and respiratory disease. 1995, 18: 227-281.
[5]
Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2015; 10(1): 89-97.
[6]
Lingyun Gao, et al. Advances in oxidative stress and chronic obstructive pulmonary disease, Chinese medical record, 2010, 11(2): 23-27.
[7]
Wang J, Lu L, Wang Y, et al. Qishenyiqi Dripping Pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation. J Ethnopharmacol. 2015, 24; 176: 375-84.
[8]
Wang Y. et al. Development of fluorescence imaging-based assay for screening cardio protective compounds from medicinal plants. Anal. Chim. Acta. 2011, 702, 87–94.
[9]
Zhang Y., Shi P., Yao H., et al. Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishenyiqi pills) in rats. Curr. Drug Metab. 2012, 13, 510–523.
[10]
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2014) [EB/OL]. http://www.goldcopd.org/Global Initiative for Chronic Obstructive Lung Disease.
[11]
Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbation of COPD. Ann Intern Med. 1987; 166: 196–204.
[12]
Jin-Ping Zheng, Fu-Qiang Wen, Nan-Shan Zhong, et al. Twice daily N-acetyl cysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomized, double-blind placebo-controlled trial. Lancet Respire Med 2014; 2: 187–94.
[13]
Li X, Sun H, Liu C, Kang J. Mucolytic and antioxidant agents for exacerbations of chronic obstructive pulmonary disease: A meta-analysis. Zhonghua Jie He He Hu Xi Za Zhi. 2015 Aug; 38(8): 600-6.
[14]
Chen JR, Wei J, Wang LY, et al. Cardio protection against ischemia/reperfusion injury by Qi Shen Yi Qi Pill ® viaameliorate of multiple mitochondrial dysfunctions. Drug Des Devel Ther. 2015 Jun 15; 9: 3051-66.
[15]
Hui Huang, li hua Li, et al. study of Qishenyiqi Dripping Pill treatment of chronic pulmonary heart disease. Journal of integrative medicine heart cerebrovascular disease. 2008, 6(5): 509-510.
[16]
LV li bo. Qishenyiqi Pill Add with Enoxaparin in Patients w ith Chronic O bstructive Pulm onary Disease Study of Prothrom botic State R andom Parallel C ontrol. Journal of practical tranitional Chinese internal medicine. 2013, 27(9): 29-31.
[17]
Longtao, li ying. Effects of Qishenyiqi Dripping Pills on Idiopathic Pulmonary Fibrosis. Chinese general practice, 2009, 12(3): 430-432.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186